IN2012DN02241A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02241A
IN2012DN02241A IN2241DEN2012A IN2012DN02241A IN 2012DN02241 A IN2012DN02241 A IN 2012DN02241A IN 2241DEN2012 A IN2241DEN2012 A IN 2241DEN2012A IN 2012DN02241 A IN2012DN02241 A IN 2012DN02241A
Authority
IN
India
Prior art keywords
peptide
enzyme
binding
binds
amino
Prior art date
Application number
Other languages
English (en)
Inventor
Paul James Davis
James Alexander Schouten
Original Assignee
Mologic Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mologic Ltd filed Critical Mologic Ltd
Publication of IN2012DN02241A publication Critical patent/IN2012DN02241A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
IN2241DEN2012 2009-09-23 2010-09-23 IN2012DN02241A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0916749.5A GB0916749D0 (en) 2009-09-23 2009-09-23 Peptide cleaning agents
PCT/GB2010/001796 WO2011036457A1 (fr) 2009-09-23 2010-09-23 Agent peptidique de clairance

Publications (1)

Publication Number Publication Date
IN2012DN02241A true IN2012DN02241A (fr) 2015-08-21

Family

ID=41327500

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2241DEN2012 IN2012DN02241A (fr) 2009-09-23 2010-09-23

Country Status (16)

Country Link
US (1) US8846861B2 (fr)
EP (1) EP2470216A1 (fr)
JP (1) JP2013505287A (fr)
KR (1) KR20120084298A (fr)
CN (1) CN102665768B (fr)
AU (1) AU2010299643B2 (fr)
BR (1) BR112012006389A2 (fr)
CA (1) CA2774081A1 (fr)
GB (1) GB0916749D0 (fr)
IL (1) IL218713A0 (fr)
IN (1) IN2012DN02241A (fr)
MX (1) MX2012003565A (fr)
NZ (1) NZ598802A (fr)
SG (1) SG179015A1 (fr)
WO (1) WO2011036457A1 (fr)
ZA (1) ZA201201527B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2435510A (en) 2006-02-23 2007-08-29 Mologic Ltd Enzyme detection product and methods
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
EP2603520A4 (fr) 2010-08-10 2014-02-19 Ecole Polytech Agents thérapeutiques se liant aux érythrocytes
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
SG11201606761RA (en) 2014-02-21 2016-09-29 Ecole Polytecnique Federale De Lausanne Epfl Epfl Tto Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
WO2018232176A1 (fr) 2017-06-16 2018-12-20 The University Of Chicago Compositions et procédés d'induction d'une tolérance immunitaire
EP3790577A4 (fr) 2018-05-09 2022-04-27 The University of Chicago Compositions et procédés d'induction d'une tolérance immunitaire
WO2021155317A1 (fr) 2020-01-31 2021-08-05 Avilar Therapeutics, Inc. Composés se liant à l'asgpr pour la dégradation de protéines extracellulaires
KR20240017423A (ko) 2021-05-03 2024-02-07 아빌라 테라퓨틱스, 인크. 이뮤노글로불린 및 다른 단백질의 분해를 위한 강력한 asgpr-결합 화합물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075010A (en) 1992-06-09 2000-06-13 Neorx Corporation Small molecular weight ligand-hexose containing clearing agents
US4859449A (en) 1987-09-14 1989-08-22 Center For Molecular Medicine And Immunology Modified antibodies for enhanced hepatocyte clearance
US20030068322A1 (en) 1988-04-18 2003-04-10 Immunomedics, Inc. Methods of antibody-directed enzyme-prodrug therapy
EP0538268A4 (en) 1990-05-11 1993-05-12 The University Of Connecticut Targeted protection from cytotoxins
GB9324807D0 (en) 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US6172045B1 (en) * 1994-12-07 2001-01-09 Neorx Corporation Cluster clearing agents
ATE458499T1 (de) 1995-06-07 2010-03-15 Immunomedics Inc Verbesserte abgabe von diagnostischen und therapeutischen stoffen an einem zielort
GB9524942D0 (en) * 1995-12-06 1996-02-07 Aepact Ltd Drug therapy
CA2270394A1 (fr) * 1996-10-31 1998-05-07 Novalon Pharmaceutical Corporation Identification de medicaments au moyen de bibliotheques combinatoires complementaires
GB9624993D0 (en) * 1996-11-30 1997-01-15 Aepact Ltd Tumour therapy
US7138103B2 (en) 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
AU6059699A (en) * 1998-09-23 2000-04-10 Regents Of The University Of California, The Synthetic peptides, conjugation reagents and methods
DK1379634T3 (en) * 2001-04-20 2018-03-19 The Univ Of Georgia Research Foundation Inc ACTIVE LOCATION INACTIVATORS
JP2009509535A (ja) * 2005-09-27 2009-03-12 アムニクス， インコーポレイテッド タンパク様薬剤およびその使用
EP2050761B1 (fr) 2007-10-16 2011-06-29 Toscana Biomarkers S.r.l. Peptides galactosylés, leur préparation et utilisation pour le diagnostic de maladies auto-immunes

Also Published As

Publication number Publication date
MX2012003565A (es) 2012-08-03
EP2470216A1 (fr) 2012-07-04
CN102665768B (zh) 2015-01-21
NZ598802A (en) 2013-10-25
IL218713A0 (en) 2012-05-31
US8846861B2 (en) 2014-09-30
KR20120084298A (ko) 2012-07-27
AU2010299643A1 (en) 2012-03-22
CA2774081A1 (fr) 2011-03-31
GB0916749D0 (en) 2009-11-04
CN102665768A (zh) 2012-09-12
BR112012006389A2 (pt) 2016-11-22
SG179015A1 (en) 2012-04-27
ZA201201527B (en) 2013-05-29
JP2013505287A (ja) 2013-02-14
AU2010299643B2 (en) 2014-06-26
US20130053543A1 (en) 2013-02-28
WO2011036457A1 (fr) 2011-03-31

Similar Documents

Publication Publication Date Title
IN2012DN02241A (fr)
Camargo et al. Bradykinin-potentiating peptides: beyond captopril
WO2009105671A3 (fr) Procédés et compositions liés aux peptides et aux protéines avec des éléments c-terminaux
WO2011005540A8 (fr) Procédés et compositions utilisant des peptides et des protéines dotés d'éléments c-terminaux
WO2012050896A3 (fr) Ensembles supramoléculaires à site de protéase sélectifs
IN2012DN02981A (fr)
CA2766039A1 (fr) Formulations d'arginase et procedes
NZ737844A (en) Vista regulatory t cell mediator protein, vista binding agents and use thereof
CO6650414A2 (es) Grupos objetivos de receptro de complemento 2 mejorados
WO2010096838A3 (fr) Proprotéines et leurs procédés d'utilisation
WO2011097381A3 (fr) Enzymes génétiquement modifiées par des enzymes méthionine-gamma-lyase, et préparations pharmacologiques associées
BR112012019924A2 (pt) polipeptídeos de ligação de agonista de dr5.
WO2009155556A3 (fr) Peptides de ciblage de crkl
MX2009002787A (es) Composiciones y métodos para prevenir el cáncer con cupredoxinas.
IN2012DN05145A (fr)
Ferrario Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin–angiotensin–aldosterone system: antihypertensive effects and benefits beyond BP control
WO2009015382A3 (fr) Peptides novateurs qui amplifient la perméabilité de nexus
WO2006010070A3 (fr) Compositions et procedes lies a des peptides se liant de facon selective avec des cellules de la leucemie
WO2011048503A3 (fr) Peptides qui se lient au récepteur de l'alpha-fetoprotéine (afp) et leurs utilisations
Tóth et al. Opiorphin highly improves the specific binding and affinity of MERF and MEGY to rat brain opioid receptors
MX2015005867A (es) Moleculas de transporte especificas de proteoglicano c4s.
WO2012033993A3 (fr) Procédés de dosage des activités enzymatiques
WO2011021001A8 (fr) Conjugués peptidiques comportant une séquence polyhistidine et de la cystéine libre, et leurs utilisations en imagerie
WO2009077755A3 (fr) Construction de protéine associée à la latence comprenant un site de clivage sensible à l'aggrécanase
WO2005120588A3 (fr) Peptides delivres a des noyaux cellulaires